Press Releases from Myasthenia Gravis (MG) Therapeutics -Pharma Proff (1 total)
Myasthenia Gravis (MG) Therapeutics Pipeline to Witness Remarkable Growth due to …
MG is a neuromuscular disorder, which weakens muscles by decreasing number of acetylcholine receptors at the neuromuscular junction. The disease becomes prominent during adulthood; but symptoms can be observed at any age. People suffering from MG show weakness and drooping of the eyelids, resulting in double vision and excessive fatigue caused after physical work. The disease can be detected by physical examination and diagnostic imaging tests.
Soliris by Alexion Pharmaceuticals Inc.…
